Literature DB >> 17590917

Pioglitazone and nonalcoholic steatohepatitis.

Guenther Boden.   

Abstract

Entities:  

Year:  2007        PMID： 17590917     DOI： 10.1007/s11892-007-0034-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  22 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.

Authors:  Krista A King; Valerie E Levi
Journal:  Am J Health Syst Pharm       Date:  2004-02-15       Impact factor: 2.637

3.  Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver.

Authors:  Guenther Boden; Pengxiang She; Maria Mozzoli; Peter Cheung; Kiranmai Gumireddy; Prekumar Reddy; Xiaqin Xiang; Zhijan Luo; Neil Ruderman
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

4.  Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

Authors:  Guenther Boden; Carol Homko; Maria Mozzoli; Meijuan Zhang; Karen Kresge; Peter Cheung
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 5.  Peroxisome proliferator-activated receptor gamma and metabolic disease.

Authors:  T M Willson; M H Lambert; S A Kliewer
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

6.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

8.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

Authors:  Mirja Tiikkainen; Anna-Maija Häkkinen; Elena Korsheninnikova; Tuulikki Nyman; Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

Review 9.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Authors:  Sunder Mudaliar; Anna R Chang; Robert R Henry
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

10.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors:  T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.